IWP-2

For research use only. Not for use in humans.

目录号：S7085

CAS No. 686770-61-6

IWP-2是一种Wnt信号和分泌抑制剂，无细胞试验中IC50为27 nM，选择性阻断Porcn介导的Wnt棕榈酰化，一般不影响Wnt/β-catenin，且对Wnt刺激的细胞反应没有影响。IWP-2可特定低抑制 CK1δ。

规格

价格

库存

购买数量

10mg	RMB 806.41	现货
50mg	RMB 2766.42	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的IWP-2发表文献45篇：

Cell Stem Cell, 2019, 24(3):447-461.e8.

PubMed: 30661960 ( click the link to review the publication )

Nature, 2017, 545(7652):54-59

PubMed: 28445465 ( click the link to review the publication )

Nature, 2016, 10.1038/nature17408

PubMed: 26982723 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2551

PubMed: 33953173 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:644667

PubMed: 33768096 ( click the link to review the publication )

Stem Cell Res Ther, 2021, 12(1):208

PubMed: 33762018 ( click the link to review the publication )

Sci Rep, 2021, 11(1):6934

PubMed: 33767215 ( click the link to review the publication )

Commun Biol, 2021, 4(1):357

PubMed: 33742113 ( click the link to review the publication )

Nat Neurosci, 2021, 24(3):343-354

PubMed: 33558694 ( click the link to review the publication )

Cell Res, 2020, 1-18

PubMed: 32913304 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5550

PubMed: 33144563 ( click the link to review the publication )

Biomaterials, 2020, 249:120015

PubMed: 32311594 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107870

PubMed: 32640235 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038/s41418-020-00643-5

PubMed: 33116297 ( click the link to review the publication )

Eur J Nucl Med Mol Imaging, 2020, 10.1007/s00259-020-05087-0

PubMed: 33216174 ( click the link to review the publication )

Cells, 2020, 9(10)E2288

PubMed: 33066405 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):431

PubMed: 33008480 ( click the link to review the publication )

FEBS J, 2020, 10.1111/febs.15675

PubMed: 33340237 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(9):e0008602

PubMed: 32886656 ( click the link to review the publication )

Circ J, 2020, 10.1253/circj.CJ-20-0881

PubMed: 32981925 ( click the link to review the publication )

J Mol Histol, 2020, 10.1007/s10735-020-09926-0

PubMed: 33179120 ( click the link to review the publication )

Nat Biotechnol, 2020, 38(12):1421-1430

PubMed: 33273741 ( click the link to review the publication )

Elife, 2020, 9:e56434

PubMed: 32749219 ( click the link to review the publication )

Nat Neurosci, 2019, 22(3):484-491

PubMed: 30692691 ( click the link to review the publication )
Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Cell Rep, 2019,

PubMed: 31825822 ( click the link to review the publication )

Elife, 2019, 8e50208

PubMed: 31482846 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2019, 13:414-430

PubMed: 31061832 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 115:105578

PubMed: 31374250 ( click the link to review the publication )

Nat Protoc, 2018, 13(9):2062-2085

PubMed: 30202107 ( click the link to review the publication )

Protein Cell, 2018, 9(11):945-965

PubMed: 29968158 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 59(1):65-76

PubMed: 29345973 ( click the link to review the publication )

Shock, 2018, 50(6):627-639

PubMed: 29485473 ( click the link to review the publication )

Stem Cell Reports, 2018, 11(2):410-424

PubMed: 30017821 ( click the link to review the publication )

Biomater Sci, 2017, 5(9):1810-1819

PubMed: 28657075 ( click the link to review the publication )

J Am Heart Assoc, 2017, 6(8)

PubMed: 28754655 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):474-480

PubMed: 28870803 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(1):49-56

PubMed: 28242196 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(46):13150-13155

PubMed: 27799526 ( click the link to review the publication )

Int J Cardiol, 2016, 203:964-71

PubMed: 26625322 ( click the link to review the publication )

Methods, 2016, 101:103-12

PubMed: 26364591 ( click the link to review the publication )

Oncotarget, 2016, 7(31):50401-50416

PubMed: 27391060 ( click the link to review the publication )

Sci Rep, 2016, 6:32770

PubMed: 27596264 ( click the link to review the publication )

Methods, 2015, S1046-2023(15)30081-5

PubMed: 26364591 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(52):E5039-48

PubMed: 24248365 ( click the link to review the publication )

产品安全说明书

Wnt/beta-catenin抑制剂选择性比较

生物活性

产品描述

特性

Selective inhibitor of Porcn-mediated Wnt secretion.

靶点

Wnt ^[1] (Cell-free assay)	^M82FCK1δ ^[3] (Cell-free assay)
27 nM	40 nM

体外研究

IWP-2在再生医学和抗癌方面都非常有效。IWP-2使Porcn失活, Porcn是一种与O-酰基转移酶(MBOAT)结合的膜,且选择性抑制Wnt棕榈酰化。IWP-2抑制Lrp6受体和Dvl2发生Wnt依赖性的磷酸化，也抑制β-catenin累积。^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
mouse L cells	MXvGeY5kfGmxbjDhd5NigQ>?	NWjDVZFkOjRiaB?=	M3XYVmlvcGmkaYTpc44hd2ZicH;yZ5VxcW6nLX3l[IlifGWmIGfueEB{cWewYXzsbY5oKGmwIH3veZNmKExiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JHNxemmwZ3XyTY1i\2W\|LWTvdIZt[XOqIILldI9zfGW{IHHzd4F6NCCHQ{WwQVMxKG6P	MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{ezOlUoRjJ\|NEe3N\|Y2RC:jPh?=
HEK293T	NEPpNWxHfW6ldHnvckBie3OjeR?=	MV6yNkBpenN?	NV73SJZlUW6qaXLpeIlwdiCxZjDwc5JkfXCrbnWgbY4hUEWNMkmzWEBk\WyuczD0doFve2[nY4Tl[EB4cXSqIGfueFNCNWW6cILld5NqdmdidnXjeI9zKGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKFewdD;i[ZRiNWOjdHXubY4he2mpbnHsbY5oKGGodHXyJFIzKGi{czDifUBUfXCncj30c5Ah\myjc3igdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvOTV5IN88UU4>	MofGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4M{CzOlYoRjJ7NkOwN\|Y3RC:jPh?=
MIAPaCa2	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NXz3UlRNPDhiaILz	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQWDhR4EzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGVEPTBiPTCxMlkh\|ryPLh?=	MkDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4M{CzOlYoRjJ7NkOwN\|Y3RC:jPh?=
SW620	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	M3;OT\|Q5KGi{cx?=	NGDjd5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXOlIxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGVEPTBiPTCxMlkh\|ryPLh?=	NHfPVpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[zNFM3Pid-Mkm2N\|A{PjZ:L3G+
Capan1	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MXW0PEBpenN?	NWXTPW5qSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDZZBidjFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFIvODVizszNMi=>	M1XZN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkOwN\|Y3Lz5{OU[zNFM3PjxxYU6=
PANC1	MoTDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MnGzOFghcHK\|	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCDTlOxJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFXDOVAhRSB{LkOzJO69VS5?	NVPPbItyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2N\|A{PjZpPkK5OlMxOzZ4PD;hQi=>
HEK293	Ml3rRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MUS0PEBpenN?	NGPDR4xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjFT\|I6OyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBGSzVyIE2gNk44PiEQvF2u	NFz5RZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[zNFM3Pid-Mkm2N\|A{PjZ:L3G+
Panc89	M4TyN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7	MXu0PEBpenN?	M2nGWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUHHuZ\|g6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGVEPTBiPTCzMlg3KM7:TT6=	M1uxNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkOwN\|Y3Lz5{OU[zNFM3PjxxYU6=
HT-29	NUDqT3VKSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	NIXP[ng1QCCqcoO=	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFXDOVAhRSB2Lk[3JO69VS5?	M1;PSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkOwN\|Y3Lz5{OU[zNFM3PjxxYU6=
A818-6	M3vG[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MkflOFghcHK\|	Ml3TRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDOEG4MVYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygSWM2OCB;IEiuPVYh\|ryPLh?=	NVrFNZJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2N\|A{PjZpPkK5OlMxOzZ4PD;hQi=>
A673	NFntfZByUFSVIHHzd4F6		NHf0eoNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NUPaXlZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	M3jDTpFJXFNiYYPzZZk>		NGHqUIxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	NVXHOGlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MWfxTHRUKGG\|c3H5		MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	M2Hi[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	M3\LbJFJXFNiYYPzZZk>		MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MmHrdWhVWyCjc4PhfS=>		NE\zWGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NELP[WI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	NYjGRodWeUiWUzDhd5NigQ>?		NX[xbmp5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MYnxTHRUKGG\|c3H5		M3K4OZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGRCV1liY3XscJM>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NYizO4p[eUiWUzDhd5NigQ>?		NXvsbIh[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	NYn6NYp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M4L4fJFJXFNiYYPzZZk>		NEXwbJNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	MlnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MU\xTHRUKGG\|c3H5		NFnFTppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	NXfCcJZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells	MmS2dWhVWyCjc4PhfS=>		NHTzcFJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBkd262cn;sJGhpKHerbHSgeJlx\SCoaXLyc4Jt[XO2IHPlcIx{	NV\YSVlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NVf5dpNZeUiWUzDhd5NigQ>?		M2XTVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	NHzOXI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NXzWXWR{eUiWUzDhd5NigQ>?		MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NYjoS2J6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M2\UN5FJXFNiYYPzZZk>		NWfWPXVDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	M3;D[JFJXFNiYYPzZZk>		Mnv5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NITQZVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	M{DVbpFJXFNiYYPzZZk>		NGrWe4NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	M4TmWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	M{DUN5FJXFNiYYPzZZk>		MmrZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	NEi1V4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MMP7; PubMed: 24325363 Mol Cancer β-catenin inhibitor inhibited the expression of MMP7 in Bel7402 cells. Bel7402 cells were treated without or with various concentration of β-catenin inhibitor (IWP-2) for 24 h, and then the whole cell lysates were analyzed by western blotting for MMP7 exp䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖 c-myc / Cyclin D1 / Survivin; PubMed: 23761839 Oncol Lett Western blot for key regulators of the Wnt/β-catenin signaling pathway. The cells were treated with IWP-2 for 3 days. P<0.05, P<0.01 and **P<0.001. Wnt5-a/b / β-catenin / Axin2; PubMed: 27119499 Oncotarget A549 cells were harvested, and Western blot analysis was conducted for β-catenin, Wnt5-a/b, NKD2, and Axin2 with or without IWP-2	24325363 23761839 27119499

细胞实验： ^[1]	- 合并 Cell lines: L-Wnt-STF cells Concentrations: 5 μM Incubation Time: 24 h Method: L-Wnt-STF cells that exhibit constitutive Wnt pathway activation were incubated with IWR (10μM) and IWP (5μM) compounds for 24 hrs prior to lysis. Cellular lysates were subjected to Western blot analysis. (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: Crl:CD1 (ICR) and FVB/N female mice Dosages: 50 µg Administration: s.c. (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMF	22 mg/mL warmed (47.14 mM)
	DMSO	4 mg/mL warmed (8.57 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download IWP-2 SDF

分子量	466.6
化学式	C₂₂H₁₈N₄O₂S₃
CAS号	686770-61-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

定制您的化合物库

IWP-2

客户使用Selleck生产的IWP-2发表文献45篇：

产品安全说明书

Wnt/beta-catenin抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download IWP-2 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

Wnt/beta-catenin Signaling Pathway Map

相关Wnt/beta-catenin产品